Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XGN

XGN - Exagen Inc Stock Price, Fair Value and News

$4.07-0.24 (-5.57%)
Market Closed

45/100

XGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

45/100

XGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.3

Target 3M

$4.52

Target 6M

$4.45

XGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XGN Price Action

Last 7 days

-13.9%

Last 30 days

-31.9%

Last 90 days

-65.4%

Trailing 12 Months

0.3%

XGN RSI Chart

XGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XGN Valuation

Market Cap

92.2M

Price/Earnings (Trailing)

-4.84

Price/Sales (Trailing)

1.45

Price/Free Cashflow

-8.39

XGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.3

Target 3M

$4.52

Target 6M

$4.45

XGN Fundamentals

XGN Revenue

Revenue (TTM)

63.6M

Rev. Growth (Yr)

37.87%

Rev. Growth (Qtr)

0.24%

XGN Earnings

Earnings (TTM)

-19.0M

Earnings Growth (Yr)

-40.95%

Earnings Growth (Qtr)

-59.65%

XGN Profitability

Return on Equity

-104.97%

Return on Assets

-30.31%

Free Cashflow Yield

-11.92%

XGN Investor Care

Shares Dilution (1Y)

28.50%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202556.7M58.9M63.6M0
202455.7M56.7M55.8M55.6M
202346.4M52.9M51.6M52.5M
202248.1M42.9M45.4M45.6M
202143.0M46.8M48.3M48.3M
202040.7M39.2M39.5M42.0M
201934.4M36.4M38.4M40.4M
201800032.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Exagen Inc

XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
 CEO
 WEBSITEexagen.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES199

Exagen Inc Frequently Asked Questions

XGN is the stock ticker symbol of Exagen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Exagen Inc is 92.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether XGN is over valued or under valued. Whether Exagen Inc is cheap or expensive depends on the assumptions which impact Exagen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XGN.

As of Wed Jan 28 2026, XGN's PE ratio (Price to Earnings) is -4.84 and Price to Sales (PS) ratio is 1.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XGN PE ratio will change depending on the future growth rate expectations of investors.